Status:
COMPLETED
Tranexamic Acid in Total Hip Arthroplasty.
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Hip Arthroplasty
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare a single preoperative dose of 1g of tranexamic acid (TXA) versus a preoperative dose of 1g of TXA followed by a continuous infusion of 1g over height hours on b...
Detailed Description
The purpose of this study is to compare a single preoperative dose of 1g of tranexamic acid (TXA) versus a preoperative dose of 1g of TXA followed by a continuous infusion of 1g over eight hours on bl...
Eligibility Criteria
Inclusion
- Patient requiring hip arthroplasty in first line, except recent hip fracture (less than 3 months)
- Consent of the patient or a family member or the support person.
Exclusion
- Contraindication to tranexamic acid.
- Contraindication to apixaban.
- Pregnancy.
- Patient receiving a curative anticoagulating treatment in the preoperative period.
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT02252497
Start Date
April 1 2014
End Date
January 1 2016
Last Update
March 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055